NEW YORK, May 14, 2018 /PRNewswire/ -- WeissLaw LLP is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of ARMO BioSciences
Inc. ("ARMO" or the "Company") (NASDAQ: ARMO) in connection with
the proposed acquisition of the Company by Eli Lilly & Co.
("LLY") (NYSE: LLY). Under the terms of the acquisition
agreement ARMO shareholders will receive $50.00 in cash for each share they own.
WeissLaw is investigating whether ARMO's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, at least one analyst set a target price of
$75.00 per share, or $25.00 above the offer price. Moreover, the
deal is a strategic transaction that will expand LLY's drug
portfolio and provide LLY a foothold in the very lucrative cancer
immunotherapy industry.
Given these facts, WeissLaw is investigating whether ARMO's
Board acted in the best interests of ARMO's public shareholders to
maximize shareholder value prior to entering into the
agreement. If you own ARMO shares and would like more
information about your rights or our investigation, or if you have
information to share with us, please contact Joshua Rubin by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the form
on our website,
http://www.weisslawllp.com/armo-biosciences-inc/
View original
content:http://www.prnewswire.com/news-releases/weisslaw-llp-armo-biosciences-inc-acquisition-may-not-be-in-the-best-interests-of-armo-shareholders-300647750.html
SOURCE WeissLaw LLP